Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with or without Tremelimumab in recurrent endometrial cancer
NCT03015129Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2017
- Primary completion
- Dec 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in endometrial carcinoma, endometrial carcinosarcoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Jan 2017; status: completed.
02
Drugs
durvalumab
03
Conditions
endometrial carcinomaendometrial carcinosarcoma
Beyond the preview
Go deeper on NCT03015129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03015129.